<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049425</url>
  </required_header>
  <id_info>
    <org_study_id>WSG AM04</org_study_id>
    <nct_id>NCT01049425</nct_id>
  </id_info>
  <brief_title>Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer</brief_title>
  <acronym>planB</acronym>
  <official_title>Randomised Comparison of Adjuvant Docetaxel / Cyclophosphamide With Sequential Adjuvant EC / Docetaxel Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West German Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>West German Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The planned trial compares an anthracycline-free taxane based regimen versus a modern third&#xD;
      generation (anthracycline/taxane-based) regimen in HER2/neu non-over expressing tumors. The&#xD;
      aim is to define a further anthracycline-free standard and to spare anthracycline toxicity to&#xD;
      a patient, who will only have a modest benefit from this compound. Prior to randomization for&#xD;
      chemotherapy for all patients with HR positive disease OncotypeDXÂ® will be performed to&#xD;
      identify patients who should not receive chemotherapy.&#xD;
&#xD;
      Secondary objectives of this trial will be to compare overall survival and toxicity between&#xD;
      the two chemotherapy arms, to evaluate survival in the observation arm and to perform&#xD;
      translational research regarding prognostic and predictive factors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2009</start_date>
  <completion_date type="Actual">May 15, 2018</completion_date>
  <primary_completion_date type="Actual">March 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival in patients treated with either 6 cycles of Docetaxel / Cyclophosphamide chemotherapy or 4 cycles of EC followed by 4 cycles of Docetaxel as adjuvant treatment</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3198</enrollment>
  <condition>Primary Breast Cancer</condition>
  <condition>Her2 Non-overexpressing</condition>
  <arm_group>
    <arm_group_label>Epirubicin and Cyclophosphamid followed by Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 cycles of EC on day one every three weeks followed by 4 cycles of Docetaxel on day one every three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination of Docetaxel and Cyclophosphamid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous infusion on day one every three weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>4 cycles, intravenous use, day 1 every three weeks</description>
    <arm_group_label>Epirubicin and Cyclophosphamid followed by Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>4 cycles, intravenous infusion, day 1 every three weeks</description>
    <arm_group_label>Epirubicin and Cyclophosphamid followed by Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy</description>
    <arm_group_label>Epirubicin and Cyclophosphamid followed by Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>6 cycles, intravenous infusion, day 1 every 3 weeks</description>
    <arm_group_label>Combination of Docetaxel and Cyclophosphamid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>6 cycles, intravenous infusion, day one every three weeks</description>
    <arm_group_label>Combination of Docetaxel and Cyclophosphamid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria(Screening):&#xD;
&#xD;
          -  Female patients, age at diagnosis 18 - 75 years&#xD;
&#xD;
          -  Histological confirmed unilateral primary invasive carcinoma of the breast&#xD;
&#xD;
          -  Adequate surgical treatment with complete resection of the tumor (R0) and resection of&#xD;
             &gt; or = 10 axillary nodes or SLN in clinically N0 patients&#xD;
&#xD;
          -  T1 - T4 (if operable, inflammatory breast cancer is excluded)&#xD;
&#xD;
          -  Her-2 non-over expressing tumor confirmed by IHC/FISH&#xD;
&#xD;
          -  Estrogen and/or progesterone receptor analysis performed on the primary tumor prior to&#xD;
             randomization. Results must be known at the time of randomization&#xD;
&#xD;
          -  Node positive disease or node negative disease with at least one other risk factor&#xD;
             (tumor size &gt; or = 2 cm, grade &gt; or = 2, ER and PR negative, high uPA//PAI-1 levels)&#xD;
&#xD;
          -  No evidence for distant metastasis (M0) after conventional staging&#xD;
&#xD;
          -  Performance Status ECOG &lt; or = 1 or KI &gt; or = 80 %&#xD;
&#xD;
          -  The patient must be accessible for treatment and follow-up&#xD;
&#xD;
          -  Written informed consent for central pathology review and evaluation of Recurrence&#xD;
             Score (HR positive) and participation in the planB trial prior to beginning specific&#xD;
             protocol procedures&#xD;
&#xD;
        HR positive patients:&#xD;
&#xD;
          -  Patient willingness to participate in adjuvant chemotherapy planB trial if RS &gt; 11&#xD;
&#xD;
          -  Indication for chemotherapy given provided either &gt; 4 involved lymph nodes or RS &gt; 11&#xD;
             in 1-3 lymph nodes or N0 disease&#xD;
&#xD;
        Additional Inclusion Criteria (Randomisation to chemotherapy):&#xD;
&#xD;
          -  Laboratory requirements (within 21 days prior to randomization):&#xD;
&#xD;
               -  Leucocytes &gt; or = 3.5 109/L&#xD;
&#xD;
               -  platelets &gt; or = 100 109/L&#xD;
&#xD;
               -  haemoglobin &gt; or = 10 g/dL&#xD;
&#xD;
               -  total bilirubin &lt; or = 1 ULN&#xD;
&#xD;
               -  ASAT (SGOT) and ALAT (SGPT) &lt; or = 2.5 UNL&#xD;
&#xD;
               -  creatinine &lt; 175 ymol/L (2 mg/dL)&#xD;
&#xD;
          -  Negative pregnancy test (urine or serum) within 7 days prior to randomization in&#xD;
             premenopausal patients&#xD;
&#xD;
          -  LVEF within normal limits of each institution measured by echocardiography or MUGA&#xD;
             scan and&#xD;
&#xD;
        Exclusion Criteria(Screening):&#xD;
&#xD;
          -  HER2 over expression confirmed by IHC/FISH/CISH&#xD;
&#xD;
          -  Known hypersensitivity reaction to the compounds or incorporated substances&#xD;
&#xD;
          -  Known polyneuropathy &gt; or = grade 2&#xD;
&#xD;
          -  Severe and relevant comorbidity that would interact with the application of cytotoxic&#xD;
             agents or the participation in the study including acute cystitis and ischuria and&#xD;
             chronic kidney disease.&#xD;
&#xD;
          -  Prior malignancy with a disease-free survival of &lt; 10 years, except curatively treated&#xD;
             basalioma of the skin, pTis of the cervix uteri or ipsilateral ductal carcinoma&#xD;
             in-situ (DCISpTis of the breast)&#xD;
&#xD;
          -  Non-operable breast cancer including inflammatory breast cancer&#xD;
&#xD;
          -  Previous or concurrent treatment with cytotoxic agents for any reason after&#xD;
             consultation with the sponsor&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs. Participation in another clinical&#xD;
             trial with any investigational not marketed drug within 30 days prior to study entry&#xD;
&#xD;
          -  Male breast cancer&#xD;
&#xD;
          -  Concurrent pregnancy; patients of childbearing potential must implement a highly&#xD;
             effective (less then 1% failure rate) non-hormonal contraceptive measures during the&#xD;
             study treatment&#xD;
&#xD;
          -  Breast feeding woman&#xD;
&#xD;
          -  Sequential breast cancer&#xD;
&#xD;
          -  Lack of patient compliance&#xD;
&#xD;
        Additional Exclusion Criteria (Randomisation):&#xD;
&#xD;
          -  Inadequate organ function including:&#xD;
&#xD;
               -  Leucocytes &lt; 3,5 G/l&#xD;
&#xD;
               -  platelets &lt; 100 G/l&#xD;
&#xD;
               -  creatinine or bilirubin above normal limits&#xD;
&#xD;
               -  alkaline phosphatise &gt; 5 UNL&#xD;
&#xD;
               -  ASAT and/or ALAT associated with AP &gt; 2.5 UNL&#xD;
&#xD;
               -  uncompensated cardiac function&#xD;
&#xD;
          -  Time since axillary dissection &gt; 42 days&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike A. Nitz, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ev. Krankenhaus Bethesda Moenchengladbach</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadia Harbeck, Prof. Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bethesda Krankenhaus</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anthracycline-free</keyword>
  <keyword>OncotypDX</keyword>
  <keyword>taxane</keyword>
  <keyword>Her2 negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

